Credit Suisse’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

Credit Suisse’s Portfolio FUSN Stock Details FUSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$873K	Buy	+40,935	New	+$490K	﹤0.01%	2345

Other funds holding FUSN

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Credit Suisse's FUSN Position: Q1 2024 in Review

Credit Suisse opened a new position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q1 2024: 40,935 shares worth $873K. The stake represents ﹤0.01% of the portfolio and ranks #2345 among its holdings.

114 funds tracked by Wall St. Rank hold FUSN as of Q1 2024.

Credit Suisse held 40,935 shares of Fusion Pharmaceuticals Inc. Common Shares worth $873K as of Q1 2024.
Fusion Pharmaceuticals Inc. Common Shares was a new Credit Suisse position in Q1 2024.
Fusion Pharmaceuticals Inc. Common Shares made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2345 holding.
114 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.